| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.2310/7750.2009.00010 |
| P698 | PubMed publication ID | 19480752 |
| P50 | author | Michele Ramien | Q57163606 |
| P2093 | author name string | Alain Brassard | |
| P2860 | cites work | Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial | Q28374317 |
| Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial | Q30829854 | ||
| Raynaud's phenomenon | Q34299550 | ||
| Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients | Q34559161 | ||
| Treatment of scleroderma skin ulcers using becaplermin gel and hydrocolloid membrane | Q34691765 | ||
| Treatment of scleroderma: an update | Q35073374 | ||
| Treatment of cutaneous calcinosis in limited systemic sclerosis with minocycline | Q35552480 | ||
| Low dose warfarin treatment for calcinosis in patients with systemic sclerosis | Q35553349 | ||
| Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study | Q35709373 | ||
| Statins and the vasculopathy of systemic sclerosis: potential therapeutic agents? | Q36336259 | ||
| Systemic sclerosis: hypothesis-driven treatment strategies | Q36484155 | ||
| Therapeutic options for digital ulcers in patients with systemic sclerosis | Q36835012 | ||
| Does this patient with diabetes have osteomyelitis of the lower extremity? | Q37088800 | ||
| Management of sclerodermal finger ulcers | Q39351914 | ||
| Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study | Q39369921 | ||
| A placebo-controlled study on urokinase therapy in systemic sclerosis | Q39437329 | ||
| Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study | Q39465072 | ||
| Systemic sclerosis in 3 US ethnic groups: a comparison of clinical, sociodemographic, serologic, and immunogenetic determinants | Q39563893 | ||
| Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis | Q39576780 | ||
| Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. | Q39632069 | ||
| Cigarette smoking as a significant risk factor for digital vascular disease in patients with systemic sclerosis. | Q39637753 | ||
| Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. | Q39702715 | ||
| Autoantibodies in systemic sclerosis | Q39726030 | ||
| A pilot trial of treprostinil for the treatment and prevention of digital ulcers in patients with systemic sclerosis | Q39752879 | ||
| Effect of clonazepam on Raynaud's phenomenon and fingertip ulcers in scleroderma | Q39806660 | ||
| Comparison of patients with and without digital ulcers in systemic sclerosis: detection of possible risk factors | Q39871875 | ||
| A radical proposal for the pathogenesis of scleroderma | Q40871808 | ||
| Circulating endothelial progenitor cells and endothelial function after chronic Tadalafil treatment in subjects with erectile dysfunction | Q42492175 | ||
| Modulation of fibroblast proliferation by oxygen free radicals | Q42805525 | ||
| Oral sildenafil for the treatment of Raynaud's phenomenon and digital ulcers secondary to systemic sclerosis | Q43048503 | ||
| Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine | Q43740421 | ||
| Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study | Q43764381 | ||
| The effect of captopril on cutaneous blood flow in patients with primary Raynaud's phenomenon | Q44791515 | ||
| Successful treatment of severe Raynaud's phenomenon with bosentan in four patients with systemic sclerosis | Q45122047 | ||
| Topical opioids for painful ulcers in systemic sclerosis | Q46740212 | ||
| Statins as immunomodulators in systemic sclerosis | Q46970276 | ||
| Sustained-release transdermal glyceryl trinitrate patches as a treatment for primary and secondary Raynaud's phenomenon. | Q47642113 | ||
| Bosentan as a rescue therapy in scleroderma refractory digital ulcers | Q48591305 | ||
| Guidelines for the treatment of diabetic ulcers. | Q51089215 | ||
| Treatment of severe scleroderma skin ulcers with recombinant human erythropoietin. | Q53198817 | ||
| Early detection of pulmonary arterial hypertension in systemic sclerosis: A French nationwide prospective multicenter study | Q56978308 | ||
| Skin ulcers in systemic sclerosis: Determinants of presence and predictive factors of healing | Q57753603 | ||
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | S42-8 | |
| P577 | publication date | 2009-05-01 | |
| P1433 | published in | Journal of cutaneous medicine and surgery | Q25380090 |
| P1476 | title | The challenge of scleroderma ulcers | |
| P478 | volume | 13 Suppl 1 |
Search more.